According to World Health Organization data, 7.6 million cancer deaths occurred worldwide in 2008, of which 1.4 million were due to lung cancer alone, making neoplasm of the lung the leading cause of cancer deaths (1) . The worsening of risk factors for the disease and aging of the population may be the major contributors to the fact that lung cancer has become one of the most common malignant neoplasms in the world (2) . In the absence of a reliable screening tool, less than 15% of patients are diagnosed with early stage I lung cancer, and less than 15% of all patients survive for 5 years after the diagnosis. In developing countries, more than 80% of patients are ineligible for surgical resection at diagnosis, mostly because of the advanced stage of the cancer, but also due to a poor general condition (3, 4) .
Characteristically, lung cancer at its initial development is radiologically occult. Screening using sputum cytology has been used with limited success (5). Evaluation using low-dose spiral computed tomography scanning as a screening tool for lung cancer is being studied, but limitations of this technique include high costs and the need for repeated scanning (6) . Histologic confirmation with biopsy specimens is the mainstay of lung cancer diagnosis, but patients are reluctant to undergo biopsy unless they are presented with evidence of a high likelihood of having lung cancer. Therefore, the propensity for biomarkers to be detected in serum at an early cancer stage has become an area of interest for clinicians (7, 8) , and lung cancer biomarkers are frequently assessed to assist in the screening and diagnosis of lung cancer.
A number of diagnostic biomarkers for lung cancer have been suggested (9) , including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 19 (CY-FRA-21-1), alpha-fetoprotein (AFP), serum carbohydrate antigen-125 (CA-125), carbohydrate antigen-19.9 (CA-19.9), and ferritin. These biomarkers have varied sensitivities for different subtypes of lung cancer (10, 11) . As all of these biomarkers can be measured using electrochemiluminescence immunization, we propose that combining these biomarkers may improve their clinical diagnostic sensitivity. In our study, we evaluated the efficiency of 7 biomarkers independently or in combination for the clinical diagnosis of lung cancer.
Patients and Methods
From June 2008 to October 2010, 530 patients who came to our hospital with a clinical presentation suggestive of lung cancer were included in our study. Demographic details, case history, and clinical and imaging results were collected. Histopathologically confirmed cases of lung cancer were further categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) groups. The study cohort included 149 confirmed cases of lung adenocarcinoma (77 men, 72 women), 103 confirmed cases of squamous cell carcinoma of the lung (90 men, 13 women), and 77 confirmed cases of SCLC (60 males, 17 females). A total of 201 patients (139 men, 64 women) were diagnosed with benign lung lesions (including tuberculosis, pneumonia, lung abscess, and chronic bronchitis). We also included 229 subjects (129 men, 100 women) who visited the hospital for a comprehensive health check-up and were free from any pathology, as healthy controls. The study was approved by the hospital ethical committee, and written consent was obtained from each subject for their participation in the study.
Peripheral blood (2 mL) was collected in a vacuum tube (BD Company, USA) from subjects after an overnight fast; care was taken to avoid hemolysis and lipemia formation. Each sample was centrifuged at 3000 rpm for 5 min (4 °C). The serum was separated from the sample after centrifugation and kept at 4 °C until analysis. Assays were performed within 5 days of sample acquisition. Electrochemiluminescence immunization (Roche cobas e411) was used to detect and measure biomarker concentrations. CEA and CA-125 kits were purchased from Abbott Corporation, USA. All other biomarker detection kits were purchased from ROCH Corporation, USA.
The cutoff values for the assay kits provided by the manufacturers were accepted as the clinical cutoff values. The cutoff values for the assessed markers were as follows: CEA, <3.4 ng/ mL; CA-125, <35 U/mL; CA-19.9, <39 U/mL; AFP, <7.02 ng/mL; CYFRA-21-1, <3.3 ng/mL; ferritin, <30-400 ng/mL; and NSE, <15.2 ug/L. The upper limit of the normal value was accepted as the critical value. When the measured value was higher than the critical value, the biomarker test was considered to be positive (indicating the existence of a tumor).
We used "a" to denote a true positive value (lung cancer was actually present, and biomarker test results were positive), "b" to denote a false positive value (lung cancer was actually absent, but biomarker test results were positive), "c" to denote a false negative value (lung cancer was actually present, but biomarker test results were negative), and "d" to denote a true negative value (lung cancer was actually absent, and the biomarker test results were negative). The sensitivity was calculated as a/ (a + c) × 100%, and specificity was Statistical analysis. SPSS 13.0 statistical software and MICROSOFT EXCEL were used for statistical analysis. A p value of <0.05 was considered statistically significant. Tumor biomarker levels were averaged using X ± S; differences between groups were compared using the (least significant difference) LSD-t test and detection rates were compared using the chi-square test. Receiver Operating Characteristic [ROC] curves were used to observe the area under the curve (AUC) and standard error.
Results
Biomarker expression in the study group. CEA, NSE, CYFRA-21-1, CA-125, and CA-19.9 showed the highest level of expression among all assessed biomarkers in the lung cancer group, with a statistically significant difference between the lung cancer group and the benign lung disease and healthy groups (p < 0.05); there was no significant difference between the expression levels of these biomarkers between the group with benign lung disease and healthy subjects (p > 0.05) [ Table 1 ].
Biomarker expression in the lung cancer subtypes. Biomarker levels of CEA, CA-125, and ferritin correlated with lung adenocarcinoma; while NSE expression correlated with SCLC; where as CYFRA-21-1 expression showed highest correlation with squamous cell lung cancer subtypes. There was marked disparity between expression levels of different biomarkers (p < 0.05) in the lung cancer subtypes. AFP and CA-19.9 expression levels showed no discrepancy between the different pathologic subtypes (p > 0.05). CA-125, CYFRA-21-1, and NSE had the highest independent true positive expression in adenocarcinoma, squamous cell carcinoma, and SCLC, respectively [ Table 2 ].
ROC insinuation. The AUC for CEA, NSE, CYFRA-21-1, CA-125, CA-19.9, ferritin, and AFP was 0.556 ± 0.074, 0.490 ± 0.067, 0.654 ± 0.067, 0.711 ± 0.049, 0.616 ± 0.071, 0.645 ± 0.053, and 0.471 ± 0.072, respectively. NSE and AFP had the smallest AUC, which was statistically insignificant (p > 0.05) [ Figure 1] .
Combination of biomarkers. Biomarker combinations showed varying degrees of sensitivity for the pathologic subtypes of lung cancer. CEA + NSE showed 75% sensitivity for SCLC, whereas NSE + CYFRA-21-1 and CYFRA-21-1 Difference between the groups was compared using LSD-t test in SPSS. LSD-t test results displayed "*"; when difference between two groups were statistically significant. In AFP and ferritin groups, all the P-value is above 0.05. With an increasing number of biomarkers, the detection sensitivity increased; however, this increased sensitivity appeared to be accompanied by a decreased specificity [ Table 3] .
Discussion
The expression level of 7 tumor markers was measured in 759 subjects, including 329 patients with pathologically confirmed lung cancer, 201 patients with benign lung disease, and 229 healthy controls, in order to examine the sensitivity and specificity of each biomarker in the detection of lung cancer. Combining biomarkers increased the sensitivity for lung cancer detection and provided useful insight into the pathologic subtypes. However, larger combinations were accompanied by decreased specificity.
The presence of biomarkers in the plasma of patients with lung cancer has aroused great clinical interest, since, with a simple blood test, a valid biomarker could be used for screening, diagnosis, prognosis, progression assessment, and monitoring of therapeutic response (8) . However, the lack of a uniform approach to extraction and quantification has made the standardization of any particular biomarker difficult (7) . Moreover, the presence of individual free circulating biomarkers has been reported not only in patients with lung cancer, but also in patients suffering from benign lung lesions and other malignancies, and even healthy subjects (12) (13) (14) (15) . Various hypotheses have been proposed to explain these phenomena, but researchers agree on the fact that biomarker concentrations are generally higher in patients with malignant pathologies as compared to healthy controls. More intriguing is the question of whether a biomarker combination can increase the diagnostic sensitivity in lung cancer.
Originally described by Gold et al. (16) , CEA expression has been reported to be higher in patients with glandular cancer (17) . Earlier findings (18) (19) (20) , suggested the presence of elevated CEA levels in some benign tumors and chronic conditions such as hepatic cirrhosis, colonic polyp, and smokers, we found a very high sensitivity and specificity of CEA for adenocarcinoma of the lung; a possible explanation for this observation may be our exclusion of unhealthy subjects from the control group. This finding suggests that plasma CEA levels can be used as a diagnostic marker inclusive of lung adenocarcinoma. Higher levels of AFP have previously been shown to be highly suggestive of cancer of the gastrointestinal, reproductive, and genitourinary systems. In contrast, our results did not find any significant statistical difference in the expression level of AFP and ferritin between the 3 study groups. We believe that this observation requires further evaluation.
Recent evidence (21) (22) (23) suggests the existence of a correlation between ferritin level and malignancy, with elevated serum ferritin levels observed in lymphoma, Hodgkin's disease, breast cancer, ovarian cancer, and colon cancer (24) (25) (26) . Our results demonstrate a very low level of ferritin expression in the pathologic subtypes of lung cancer; a possible explanation for this discrepancy may be the variation in the inflammatory status of the associated tissues.
It has been reported (27) that serum levels of NSE are highest in tumors of neuroendocrine origin. NSE is an isoenzyme of enolase, and a large amount of clinical data (28) (29) (30) (31) (32) (33) has confirmed its high sensitivity and specificity for SCLC. In our study, NSE levels were highest in SCLC, and NSE levels in SCLC were the highest amongst the 7 biomarkers assessed. However, the diagnostic accuracy of NSE appears to be low, as depicted by the fact that the lowest area under the ROC curve was observed for NSE. A likely explanation for this observation may be the small number of patients with SCLC that were included in our study.
CA-19.9 is an oligosaccharide, initially reported as a glycoprotein extract from the colonic mucosa by Koprowski in 1979 (34) . Recent reports suggest (35) (36) (37) (38) (39) that CA-19.9 is a more reliable biomarker for pancreatic carcinoma. Our study found the highest levels of CA-19.9 expression in adenocarcinoma and squamous cell carcinoma of the lung. These results suggest that CA-19.9 may be used as a diagnostic marker for NSCLC. Some studies (40) (41) (42) have reported elevated CA-19.9 levels in interstitial pneumonia; we believe that the augmented expression of CA-19.9 in benign lung disease may be the result of extensive damage to the lung parenchyma.
CA-125 is considered to be a diagnostic guide for tumors of the urinary system. Previous reports have indicated that the sensitivity and specificity of CA-125 in diagnosing ovarian cancer are 72% and 95%, respectively (43, 44) . However, the specificity of CA-125 in the diagnosis of malignant tumors remains controversial. In our study, the CA-125 detection rate was highest in the lung adenocarcinoma group, which is in agreement with earlier findings that CA-125 is expressed in about 51% of lung cancer tissues, with the expression level closely related to the degree of differentiation of the tumor.
CYFRA-21-1 is widespread in epithelial cells; the malignant transformation of epithelial cells activates protease, which accelerates the degradation of keratin, thereby resulting in the release of CYFRA-21-1 into the blood. It has been reported that CYFRA-21-1 expression is higher in patients with squamous cell carcinoma than in patients with glandular cancer and SCLC (45) (46) (47) (48) (49) (50) (51) . The results of our study are consistent with earlier findings, as CYFRA-21-1 showed the highest expression level in the squamous cell carcinoma group, suggesting that CYFRA-21-1 represents an efficient biomarker for the diagnosis of squamous cell carcinoma. Early reports (50, 52) showed that the combination of CYFRA-21-1 and CA-125 has a high sensitivity for squamous cell carcinoma of other body regions; however, we found that the combination of CYFRA-21-1 and NSE showed a high sensitivity for both the squamous cell carcinoma and adenocarcinoma subtypes of lung cancer. This discrepancy requires further evaluation.
Combining the evaluated biomarkers in the present study increased the detection rate of lung cancer. The 7-biomarker combination produced the highest detection rate, at 80.49% for adenocarcinoma, 94.11% for squamous cell carcinoma, 83.33% for SCLC, and 86.21% for lung cancer. Thus, it appears that the 7-biomarker combination can provide a high sensitivity (86.21%) for detecting lung cancer; however, this high sensitivity was associated with compromised specificity (26.79%). The 3-biomarker combination of CEA + NSE + CYFRA-21-1 showed the highest sensitivity (75.61%) and specificity (47.32%) for lung adenocarcinoma, which was not increased by the addition of another biomarker; rather, a decrease in specificity was observed. These observations differed from those of Molina et al., who found that CEA + CYFRA-21-1 showed the highest sensitivity for adenocarcinoma (53) . The combina-tion of NSE + CEA + CA-125 showed 83.33% sensitivity for SCLC in our study, with all other combinations associated with a clear decrease in specificity. This finding suggests that the 3-biomarker combination of NSE + CEA + CA-125 may help with the diagnosis of SCLC. The 4-biomarker combination of CEA + NSE + CYFRA-21-1 + CA-125 showed the highest sensitivity (94.11%) and specificity (83.91%) for squamous cell carcinoma, illustrating that this combination may aid in the diagnosis of this pathologic subtype. Refinements of sampling techniques and new development in tumor biomarker combination array and nanotechnology are critically important in developing combinations for diagnosis of lung cancer.
Our study has certain limitations; first there is no arm of conservative follow up. Secondly, it is a single-center study and involves a group of physicians with a similar approach. We believe that a multi-centric study will provide a better approach for the generalization of results.
Cumulatively, our findings suggest that a single biomarker may not provide sufficient clues for the detection of lung cancer. However, considering the complexity of tumor origin and the heterogeneity of tumor antigen expression, a combination of biomarkers represents a useful means of assessing the histologic subtypes of lung cancer. The optimal specificity for each lung cancer subtype may be achieved by the appropriate combination of biomarkers.
